Concert Pharmaceuticals Announces Pricing of Initial Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts. In addition, Concert has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments. The shares are scheduled to begin trading on the NASDAQ Global Market on February 13, 2014 under the ticker symbol “CNCE.”
The offering is expected to close on February 19, 2014, subject to customary closing conditions.
UBS Investment Bank and Wells Fargo Securities are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager and Roth Capital Partners is acting as co-manager for the offering.
A registration statement relating to the securities being sold in this offering has been filed with and declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus, copies of which may be obtained from UBS Investment Bank, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, or by phone at 1-888-827-7275; or Wells Fargo Securities, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York, 10152, or by email at cmclientsupport@wellsfargo.com, or by phone at 1-800-326-5897.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
Contacts
Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284
Vice President, Corporate Communications and Investor Relations
ir@concertpharma.com
Help employers find you! Check out all the jobs and post your resume.
